By Giulia Petroni 
 

Merck KGaA said Wednesday that it has extended its collaboration with Baylor College of Medicine in Houston to accelerate manufacturing of Baylor's Covid-19 vaccine candidates.

The German pharmaceuticals and chemicals company said the teams will improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate and develop a new manufacturing platform for a second candidate to accelerate the transition to phase-1 clinical trials.

"The goal for the partnership is to develop a manufacturing process and steps that would lead to a scale-up approach suitable for pilot and later industrial production," it said.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

May 27, 2020 10:13 ET (14:13 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.